Files
Abstract
The purpose of this project is to calculate a therapeutic activity that assures the limit doses are not exceeded for critical organs in patients undergoing the I-131 MIBG / AZEDRA (Progenics Pharmaceuticals, Tarrytown, NY) therapy for pheochromocytoma and paraganglioma.